• The Journal of Internal Korean Medicine
• /
• v.38 no.5
• /
• pp.842-852
• /
• 2017

Objectives: This study reports the effects of GeonChil (Rhus verniciflua stokes) pharmacopuncture in patients with dyspepsia. Method: We treated all five patients with GeonChil pharmacopuncture, acupuncture, and moxibustion and evaluated them using the Korean Gastrointestinal Symptom Rating Scale (KGSRS), which is used to assess overall gastrointestinal symptoms. Result: After treatment, the KGSRS showed improvement in all five patients. Marked improvement was seen especially in abdominal pain, heartburn, eructation, and increased flatus symptoms. Conclusion: GeonChil pharmacopuncture may represent a new treatment for the improvement of dyspepsia.

• Journal of Korean Traditional Oncology
• /
• v.24 no.2
• /
• pp.23-31
• /
• 2019

Objective : Peripheral neuropathy refers to the symptoms caused by damage to peripheral fibers, inflammation and degeneration. This study reports the effects of moxibustion, electric moxibustion, and pharmacopuncture including GeonChil(Rhus verniciflua stokes, 乾漆)and Whalhyul(活血) pharmacopuncture on patients with peripheral neuropathy induced by anti-cancer drugs and chemotherapy. Method : We administered moxibustion, electric moxibustion, GeonChil and Whalhyul pharmacopuncture to two patients who showed peripheral neuropathy induced by anti-cancer drugs and chemotherapy. The symtoms were evaluated using Visual Analog Scale (VAS) and chemotherapy induced peripheral neuropathy assessment tool (CIPNAT). Results : Following observations were made after treatments. Case 1 : After nine procedures, the score of VAS was decreased. Feeling of cold and numbness were improved, and as rotation movement of ankle was also possible, gait disturbance were improved. Case 2 : After, seven procedures symptoms of both shoulder pain were improved, and the symptoms of peripheral neuropathy were eliminated. Conclusion : We found the possibility of symptom improvement after moxibustion, electric moxibustion, and pharmacopuncture treatment on peripheral neuropathy caused by anti-cancer drugs. Clinical studies of pilot study and control settings will need to be carried out later.